Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
98,294,118
-
Total 13F shares
-
50,164,476
-
Share change
-
+19,674,795
-
Total reported value
-
$427,856,540
-
Put/Call ratio
-
0%
-
Price per share
-
$8.53
-
Number of holders
-
72
-
Value change
-
+$173,112,031
-
Number of buys
-
46
-
Number of sells
-
24
Institutional Holders of ARS Pharmaceuticals, Inc. - Common Stock (SPRY) as of Q4 2022
As of 31 Dec 2022,
ARS Pharmaceuticals, Inc. - Common Stock (SPRY) was held by
72 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
50,164,476 shares.
The largest 10 holders included
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), ORBIMED ADVISORS LLC, FMR LLC, RA CAPITAL MANAGEMENT, L.P., SR ONE CAPITAL MANAGEMENT, LP, Rubric Capital Management LP, K2 PRINCIPAL FUND, L.P., BAKER BROS. ADVISORS LP, Nextech Invest Ltd., and VANGUARD GROUP INC.
This page lists
72
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.